Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10881086

Genetically modified mouse whose genome comprises a humanized CD274 gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10875911

High affinity human antibodies to human angiopoietin-2

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10865236

Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a compl

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10863729

Rodents having a humanized TMPRSS gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10857231

Formulations of VEG antagonist fusion proteins and method of manufacturing them

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10857205

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10851158

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10844137

Anti-CTLA-4 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10829544

Human antibodies to Ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10828345

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10815305

Methods of treating inflammatory conditions

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10806780

Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10793624

Human antibodies to Bet v 1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10785966

Humanized M-CSF mice

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10787647

HSD17B13 variants and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10787501

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10785968

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10774128

IL-33 antagonists and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10772956

Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10772972

Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10765762

Humanized model of kidney and liver disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10752701

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10752690

Biologically active molecule conjugates, reagents and methods of manufacture, and therapeu

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10752702

Anti-TIE2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted